Recent Posts
News•Feb 27, 2026
FDA Approves Next-Generation CardioMEMS Reader for Heart Failure Monitoring
Abbott received FDA approval for its next‑generation CardioMEMS HERO reader, a pulmonary artery pressure device for heart‑failure patients. The HERO unit is 60% lighter than earlier readers and incorporates built‑in Wi‑Fi and cellular connectivity, allowing measurements anywhere. The upgrade builds on a platform that has already demonstrated a 57% drop in heart‑failure hospitalizations. Clinicians expect the lighter, more portable design to boost patient adherence and data quality.
By Cardiovascular Business
News•Feb 27, 2026
AI Helps Identify Risk in Adults with Congenital Heart Disease
Survival rates for congenital heart disease (CHD) have risen, creating an estimated 1.4 million adult patients who often require repeat surgeries. At the 2026 Society of Thoracic Surgeons meeting, Mayo Clinic researchers presented a machine‑learning model that isolates 15 key variables...
By Cardiovascular Business
News•Feb 27, 2026
New Heart Device for ‘No-Option’ Chest Pain Patients Shows Early Potential
VahatiCor’s A‑Flux Reducer System, a self‑expanding, recapturable coronary sinus device, was implanted in a first‑in‑human cohort of 12 patients with coronary microvascular dysfunction or obstructive CAD. Eleven procedures were completed without any device‑related complications, and patients experienced significant improvements in...
By Cardiovascular Business
News•Feb 26, 2026
Whole-Body MRI Provider Starts Offering AI-Powered CCTA Scans
TrueScan, a whole‑body MRI center in St. Peterburg, Florida, has begun offering AI‑powered coronary CT angiography (CCTA) from Heartflow, available as a standalone test or bundled with its MRI packages. The move addresses growing patient and physician demand for coronary imaging...
By Cardiovascular Business
News•Feb 26, 2026
3D Software Helps Cardiologists Plan Ahead for TAVR Complications
Sentara’s high‑volume TAVR center adopted the AI‑enabled DASI 3‑D planning platform to move beyond static CT measurements. The software dynamically simulates valve frame expansion, calcium deformation, and tissue interaction, allowing clinicians to test multiple valve sizes and depths before the...
By Cardiovascular Business
News•Feb 25, 2026
PFO Closure After Thromboembolism Linked to Strong 20-Year Outcomes
A new 20‑year follow‑up of 130 patients who received transcatheter patent foramen ovale (PFO) closure after a paradoxical embolism shows sustained safety and efficacy. The cohort, with a mean age of 46, experienced a recurrent stroke rate of 0.04 per...
By Cardiovascular Business
News•Feb 25, 2026
FDA Shares New Warning About Johnson & Johnson Heart Pumps After 4 Injuries
The FDA issued an early‑alert notice on February 3, 2026, highlighting a leak risk in Generation 1 purge cassettes used with Johnson & Johnson MedTech’s Impella RP heart‑pump sets. A leak can trigger a low‑pressure alarm, potentially causing biomaterial ingress, pump stoppage, and loss...
By Cardiovascular Business
News•Feb 23, 2026
ASE Promoting 3D Echo as a Better Way to Treat Congenital Heart Disease
The American Society of Echocardiography (ASE) is championing 3‑dimensional echocardiography as the preferred tool for diagnosing and guiding treatment of congenital heart disease. ASE is standardizing image display and terminology to align imagers, interventional cardiologists, and surgeons, and will deliver...
By Cardiovascular Business
News•Feb 23, 2026
FDA Approves New Biotronik Pacing Lead for LBBAP
Biotronik received FDA clearance for its Solia CSP S pacing lead, a device engineered specifically for left bundle branch area pacing (LBBAP). The lead combines a stylet‑driven platform with a novel fixed‑helix screw, addressing procedural simplicity and electrical performance. Approval relied on...
By Cardiovascular Business
News•Feb 19, 2026
Heart Failure Company BioVentrix Files for IPO
BioVentrix, a Massachusetts medtech firm developing the Revivent heart‑failure system, filed an IPO prospectus on Feb. 12, targeting a Nasdaq listing under BVXX. The company estimates a $10 billion valuation in the U.S. and $16 billion globally. Revivent, a minimally invasive LV reconstruction...
By Cardiovascular Business
News•Feb 19, 2026
Gore Completes Acquisition of Medtech Company Behind Next-Gen Heart Device
W. L. Gore & Associates has completed its acquisition of Conformal Medical, the developer of the investigational CLAAS AcuFORM left atrial appendage occlusion system. The deal, announced in January, makes Conformal a wholly‑owned Gore subsidiary while keeping its focus on the foam‑based...
By Cardiovascular Business
News•Feb 19, 2026
Medtronic’s RDN System Receives New Reimbursement Approval
Medtronic’s Symplicity Spyral renal denervation system has secured reimbursement approval from Japan’s Ministry of Health, Labour and Welfare, expanding coverage for resistant hypertension. The therapy, which uses radio‑frequency energy to ablate renal nerves via a single catheter, was previously approved...
By Cardiovascular Business
Deals•Feb 19, 2026
Gore Completes Acquisition of Conformal Medical
W. L. Gore & Associates, the materials‑science company, has finalized its acquisition of Conformal Medical, the developer of the CLAAS AcuFORM left atrial appendage occlusion system. Financial terms were not disclosed. Conformal Medical becomes a wholly‑owned subsidiary of Gore, continuing...
Cardiovascular Business